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Abstract
Object—Resected brain metastases have a high rate of local recurrence without adjuvant therapy.
Adjuvant whole brain radiotherapy (WBRT) remains the standard of care with the rate of local
control >90%. However, WBRT is delivered over 10–15 days, which can delay other therapy and
is associated with acute and long-term toxicities. Intra-operative permanent Cesium-131 (Cs-131)
implants can be performed at the time of surgery, thereby avoiding any additional therapy. We
evaluate the safety, feasibility and efficacy of a novel treatment approach of brain metastases with
a permanent intra-operative Cs-131 brachytherapy.
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Methods—After IRB approval, 24 patients with a newly diagnosed metastasis to the brain
(n=24) were accrued on a prospective protocol between 2010 and 2012. There were 10 frontal, 7
parietal, 4 cerebellar, 2 occipital, and 1 temporal metastases. Histology included lung (16), breast
(2), kidney (2), melanoma (2), colon (1), and cervix (1). Cs-131 stranded seeds were placed as a
permanent volume implant. Prescription dose was 80Gy at 5mm depth from the resection cavity
surface. Distant metastases were treated with stereotactic radiosurgery (SRS) or WBRT,
depending on the number of lesions. Primary end point was resection cavity freedom from
progression (FFP). Secondary end points included distant metastases FFP, median survival,
overall survival (OS), and toxicity.
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Results—Median follow-up was 19.3 months (range, 12.89 – 29.57 months). Median age was 65
years (range, 45–84 years). Median volume of resected tumor was 10.31 cc (range, 1.77 - 87.11
cc). Median number of seeds employed was 12 (range, 4–35) with median activity per seed of 3.82
mCi (range, 3.31–4.83 mCi) and total activity of 46.91 mCi (range, 15.31–130.70 mCi). Local
recurrence FFP was 100%. There was 1 adjacent leptomeningeal recurrence, resulting in a 1-year
regional FFP of 93.8% (95% CI = 63.2%, 99.1%). Distant metastasis FFP was 48.4% (95% CI =
26.3%, 67.4%). Median OS was 9.9 months (95% CI = 4.8 months, upper limit not estimated) and
1-year OS was 50.0% (95% CI = 29.1%, 67.8%). Complications included cerebrospinal fluid leak
(1), seizure (1), infection (1). There was no radiation necrosis.
Conclusions—Cs-131 post-resection permanent brachytherapy implants resulted in no local
recurrences and no radiation necrosis. This treatment approach was safe, well tolerated, and
convenient for patients, resulting in a short radiation treatment course, high response rates, and
minimal toxicity. These results merit further study with a multicenter trial.
Keywords
cesium-131 (Cs-131); brachytherapy; metastases; radiation; radiotherapy
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Introduction
Brain metastases are the most common intracranial tumors, occurring in up to 40% of cancer
patients with a rising annual incidence.8,47 It has been recently reported the brain metastases
account for ~60% of solid metastases arising primarily from lung, breast, kidney, colon and
skin melanoma causing major morbidity and mortality.34,53 In the last decade the incidence
of brain metastases has been rising, attributed to the increased length of survival from cancer
patients.58
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Without treatment, prognosis is dismal with survival of only 1–2 months. Survival can be
extended with WBRT to 3–6 months, and with either surgery and adjuvant SRS or surgery
followed by adjuvant WBRT to 11 months.19,20,29,46 Although WBRT is effective at
preventing local recurrence and controlling distant disease, it has been associated with acute
detriments in quality-of-life (QoL) measures10,32 and deterioration in neurocognitive
abilities.9,11,14,43 In addition, WBRT offers no overall survival benefit compared with local
therapy.2,45,54 For these reasons attention has turned to the option of aggressive local
therapy for oligometastatic disease, withholding the addition of salvage WBRT for disease
recurrence.
There are a variety of focal post-resection treatment strategies that are available in this
setting. Among such options are post-op SRS4,15,18,23-25,27,28,30,31,35,39,48,50,55 and intraoperative application of either permanent low-dose7,12,22,52 or temporary highdose5,40,44,51,61 radio-isotopes (generally Iodine-125 (I-125)) into the surgical cavity. Postop SRS is the more commonly used of these treatment modalities due to its wider
availability. Brachytherapy has historically utilized the I-125 radio-isotope for both
permanent and temporary seeds implants. Although I-125 has been shown to confer local
control comparable to that of post-op SRS and WBRT,5,7,12,22,40,44,51,52,61 the rates of
radiation necrosis have been critiqued. Cs-131 is a novel radio-isotope which confers both

J Neurosurg. Author manuscript; available in PMC 2015 August 01.

Wernicke et al.

Page 3

NIH-PA Author Manuscript

physical and radio-biological advantages when compared to both post-op SRS and I-125
brachytherapy. In this present study we prospectively evaluated the safety, feasibility and
efficacy of a novel treatment approach of brain metastases with a permanent intra-operative
Cs-131 brachytherapy.

Methods
Patient Selection
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Between 2010 and 2012, patients undergoing surgery for newly diagnosed brain metastatses,
in whom surgery was deemed appropriate, were accrued to an IRB approved prospective
trial and signed an informed consent. In general, selection criteria included a metastatic
tumor in which surgery was indicated either to relieve mass effect, reduce symptoms, for
diagnostic purposes or based on size > 2.5 cm. Patients had to have ECOG/Zubrod
performance status 0, 1, or 2 and expected survival ≥6months. Exclusion criteria included:
the tumor’s proximity to the chiasm, brainstem (increasing the risk of radiation treatment),
small cell cancer histology metastatic to the brain, pregnancy or unwillingness to practice a
form of birth control (i.e. abstinence, oral contraceptives, etc.) and previous history of
radiotherapy.
Treatment Technique
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Patients underwent maximally safe neurosurgical resection of lesions. The extent of
resection and whether surgery was en bloc or piecemeal was noted intra-operatively and
from post-operative MRI scans within 48 hours of surgery. During the time of surgical
resection the size of resected tumor (maximum diameter and volume), location
(supratentorial versus infratentorial), pial-based versus non-pial-based was noted. At the
time of resection, Cs-131 stranded seeds (IsoRay, Richland, WA) with an activity of 3–5
mCi were implanted with a planned dose of 80 Gy to a 5 mm depth from the surface of the
resection cavity. The implant was pre-calculated based on pre-operative data of tumor size
and our institutional physics nomogram and adjusted real time for the resulting intracavitary
volume of the resected metastasis (Figure 1A). The 10cm Cs-131 suture-stranded seeds
(0.5cm inter-seed spacing) were delivered in strings of 10 seeds per string and subsequently
cut into smaller lengths as per the nomogram and placed as a permanent volume implant
along the cavity in a tangential pattern to maintain a 7–10mm spacing between seeds. As a
result, the cavity is lined like “barrel staves” or “parallel tracks” (Figure 1B). The seeds are
then covered with Surgicel (Ethicon) to prevent seed migration and alteration of dosimetry
(Figure 1C) and Tisseel (Baxter) is used to line the cavity to limit cavity shrinkage and
further prevent seed dislodgement (Figure 1D). Within 24–48 hours post-implant, the patient
underwent a post-implant CT scan to determine dose distribution (Figure 2).
Follow Up
Follow-up exams included MRI every 2 months. At the time of disease progression the
metastases were treated with SRS or WBRT, depending on the number of lesions.
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Descriptive statistics (including mean, standard deviation, median, range, frequency,
percent) were calculated to characterize the study cohort. The primary endpoints of the trial
were local resection cavity FFP, regional FFP, distant FFP. Secondary end points included
median survival, overall survival (OS), and toxicity. The treatment response was rated based
upon follow-up MRI brain scans as compared to the prior MRI brain scans. Local FFP was
defined as the absence of new nodular contrast enhancement ≤5mm from the resection
cavity. Regional failure was defined as new or increased contrast enhancement, > 5mm from
the resection cavity. Distant failure was defined as new or increased contrast enhancement
elsewhere in the brain. All survival endpoints were defined as the time from the date of
resection and implantation of the Cs-131 brachytherapy seeds until either 1) the date of local
recurrence (for local FFP), 2) the date of regional recurrence (for regional FFP), 3) the date
of new metastasis (for distant FFP, or 4) the date of death (for OS). Patients without these
events were censored at their date of last follow-up. Kaplan-Meier survival analysis was
performed to generate survival curves for the above defined survival outcomes. Median and
one-year local FFP, regional FFP, distant FFP, and OS were estimated, as appropriate, and
95% confidence intervals were calculated to assess the precision of the obtained survival
estimates. The Spearman-rank correlation coefficient was used to evaluate the correlation
between Cs-131 brachytherapy seed characteristics of interest. All p-values are two-sided
with statistical significance evaluated at the 0.05 alpha level. All analyses were performed
using SPSS version 21.0 (SPSS Inc., Chicago, IL) and STATA Version 12.0 (StataCorp,
College Station, TX).
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Results
Patient Characteristics
Patient characteristics are summarized in Table 1. There were 14 females and 10 males with
a median age of 65 (range 45–84). The brain metastases were located in the frontal (10),
parietal (7), cerebellar (4), occipital (2), and temporal (1) regions. The histology from the
metastases was lung (16), breast (2), kidney (2), melanoma (2), colon (1), and cervix (1).
Treatment Parameters
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Details from the surgical resection on Cs-131 implant are shown in Table 2. Among the 24
patients who underwent resection and Cs-131 brachytherapy implant, all patients achieved
gross total resection (defined as resection of contrast enhancing disease). Based on the preoperative MRI the median volume of the resected tumor was 10.31 cc (range, 1.77–87.11
cc). Based on intra-operative measurements, the median volume of the cavity after tumor
resection was 3.13 cc (range, 1–17 cc) indicating a 69.6% decrease in cavity volume before
the seeds were placed. The median number of seeds employed was 12 (range, 4–35) with
median activity per seed of 3.82 mCi (range, 3.31–4.83 mCi) and total activity of 46.91 mCi
(range, 15.31–130.70 mCi).
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At the time of analysis there were 11 patients still alive and 13 deaths with a median followup of 19.3 months (range, 12.89–29.57 months). Among the 11 patients who are still alive, 8
had a primary originating from the lung, 2 from the breast, and 1 from the colon. One of
these patients was previously treated with SRS for a brain metastasis in a different area and
then implanted by the Cs-131 brachytherapy to a second lesion. Eight of these patients had
only one lesion, two patients had two lesions, and two patients had three lesions. For the 13
patients who died, there were 8 with a primary originating from the lung, 2 from the kidney,
2 from melanoma, and 1 from the cervix. These patients included 2 who had been previously
treated with SRS to a different area of the brain. Seven of these patients had one lesion, three
patients had two lesions, one patient had three lesions, and two patients had >3 lesions. The
median OS was 9.9 months (95% CI = 4.8 months, upper limit not estimated) (Figure 3).
The 1-year OS was 50.0% (95% CI = 29.1%, 67.8%).
Freedom From Progression
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There were zero cases of local recurrence within 5 mm of the resection cavity (Figure 4).
This yielded a local recurrence FFP of 100%. There was one case of regional recurrence
which yielded a 1-year regional resection cavity FFP of 93.8% (95% CI = 63.2%, 99.1%)
(Figure 5). This case of regional recurrence was evident 7 months post-implant and was
leptominengeal in origin (Figure 6). This patient was subsequently treated with SRS and is
still alive at the time of analysis. There were 12 cases of distant metastases, which yielded a
median distant metastases FFP of 7.6 months (95% CI = 4.1 months, upper limit not
estimated) and a 1-year distant metastases FFP of 48.4% (95% CI = 26.3%, 67.4%) (Figure
7). Distant progression was treated with either WBRT (1 patient) or SRS (8 patients).
Complications
Post-operatively, the patients were treated with 4mg of dexamethasone twice a day for 2
weeks. There were no instances of radiation necrosis. There was one instance of a dural tear
which required re-operation at 1.2 months post-implant. Additional complications included
one case of infection and one case of seizure.
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Surgical resection for the treatment of brain metastases has been utilized to establish a
histologic diagnosis, provide rapid relief of symptoms resulting from the mass effect of a
large tumor, and to improve local control. Unfortunately, tumor recurrence with surgery
alone has been shown to be as high as 46%.45 Rates of recurrence correlate with factors such
as tumor size, location, histology, and en bloc resection. With the addition of radiation
therapy in the post-operative setting, classically in the form of WBRT, the rates of
recurrence can be reduced to 10–20% but at the expense of the QoL and neurocognitive
deficits.9-11,14,32,43,46 For this reason, attention has been turned to the addition of focal
radiation to the resection bed in an effort to reduce the incidence of local failure.
The use of post-operative SRS to the resected surgical cavity has been increasing with a
number of recent publications appearing in the literature and several institutions adopting
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this technique as a new standard of care. 4,15,18,23-25,27,28,30,31,35,39,48,50,55 While the Phase
III trial from the North Central Cancer Treatment Group (N107C) comparing post-operative
SRS to WBRT in the post-op setting for brain metastases in progress, the results of phase I
and phase II trials demonstrated that local control of the resection cavity to be similar to
WBRT, ranging from 73–94%with an incidence of radiation necrosis ranging from 0–
10%.4,15,18,23-25,27,28,30,31,35,39,48,50,55 Intracranial distant failure was reported in 44–65% at
1 year, and death due to neurologic causes in ~25%.4,15,18,23-25,27,28,30,31,35,39,48,50,55 The
typical time frame for the delivery of post-operative SRS is between 2–6 weeks following
the surgical resection. This buffer time is needed in order to allow adequate wound healing
following the surgery and to allow the cavity to shrink to a smaller, stable size in preparation
for radiosurgery targeting. Nevertheless, the majority of the dose is administered to an
empty cavity. Likewise, the delay in treatment may be disadvantageous as radiographically
evident repopulation of tumor cells has been shown to occur in this time period.56 The ideal
target for SRS is a small round cavity. In patients with tumor cavities of irregular shape or
larger size (> 3 cm) this presents a challenge in developing of a treatment plan with a high
degree of conformality. Indeed, it has been shown that larger tumor cavities treated with
post-operative SRS have poor local control resulting from less conformal treatment
plans.1,16,37 Furthermore, the volume of irradiated tissue is a clear predictor of symptomatic
radiation necrosis in patients irradiated with SRS.6,41 For this reason, some centers suggest
that larger tumor beds be treated with hypofractionated stereotactic radiotherapy
(HSRT) .1,17,33,38,42,57
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Intra-operative interstitial brachytherapy has several theoretical and practical advantages
over SRS for improving local control of resected brain metastases. Brachytherapy allows a
high dose of radiation to be given to a localized area with a very steep dose fall-off, thus
covering the tumor bed but sparing normal brain tissue beyond the vicinity of the tumor bed.
The dose is delivered maximally to the area of microscopic tumor cells and not an empty
cavity. Prior studies have shown local control of the resection cavity to be between 80–
95%.5,7,12,22,40,44,51,52,61 For this reason, the conformality index of interstitial
brachytherapy is higher than that of post-operative SRS, a factor which has been shown to
cause failure of post-operative SRS.35,39 Having a very steep dose fall-off is a feature makes
brachytherapy a rather attractive option as it may avoid radiation necrosis of already
compromised brain .In addition, brachytherapy delivers the entire treatment (surgery plus
radiation) in one procedure, which is more convenient for the patient and may increase
patient satisfaction. The ability to deliver all the treatment in one sitting is particularly
appealing for patients who live at a far distance from a medical center, for whom travel may
be prohibitively expensive and/or time-consuming, particularly in a weakened state. Hence,
compliance may be increased. Brachytherapy is also more cost effective compared with
WBRT and SRS.59 Further, there is a radiobiological advantage to administering immediate
radiotherapy so as to preclude cancer cell repopulation which typically occurs at ~4 weeks.
Lastly, in contrast with postoperative SRS, which generally requires application of a metal
stereotactic frame affixed with screws to a patient skull, brachytherapy requires no frame or
a special fixation as it is performed at the time of surgery.
There are also radiobiological advantages to using brachytherapy. Continuous dose rate
radiation of brachytherapy at 0.3–3.5 Gy/h inhibits mitosis and causes proliferating tumor
J Neurosurg. Author manuscript; available in PMC 2015 August 01.
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cells to accumulate in G2, a radiosensitive phase of the cell cycle.21 There is less
radioresistance of hypoxic cells treated with brachytherapy secondary to impaired repair of
sublethal damage under hypoxic conditions36 and the opportunity for hypoxic cells to
become re-oxygenated during the treatment.21
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Criticisms of brachytherapy have focused on the high rates of radiation necrosis reported in
some series. Early series involved a stereotactic biopsy followed by permanent high-dose
implants22 or were performed for recurrent lesions refractory to external WBRT5,52 or
concurrent with WBRT.61 The use of brachytherapy for local control of newly resected
metastases without WBRT has been reported more recently. In these series, radiation
necrosis has been more common using high-dose temporary brachytherapy, such as the
Gliasite balloon, which reported a 23% rate of radiation necrosis.51 In the continuous lowdose permanent brachytherapy setting, 0% rates of radiation necrosis were shown by Bogart
et al., who used seeds with activity 0.32–0.45 mCi and a cumulative dose of 80–160 Gy
using a median of 13 seeds7,49 but achieved a local control of only 80%. On the other hand,
Huang et al, reported a 26% rate of radiation necrosis using a median of 43 I-125 seeds, with
a median activity of 0.79 mCi and median dose 800 Gy to the surface (200Gy to a depth of 1
cm) with a reported local control of 92%.22 These data indicate that a lower seed activity
coupled with a lower prescription dose will decrease the rate of radiation necrosis with only
a minimal impact on local control.
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We carefully took into account the aforementioned information while designing our trial
with Cs-131 so as to minimize the incidence of radiation necrosis. The lowered seed activity
of Cs-131 and a dose prescription in our study did not only achieve a high rate of local
control but resulted in no incidence of radiation necrosis. The rationale behind employing
Cs-131instead of I-125 lies in several physical and radiobiological advantages of the former.
Whereas I-125 has a dose rate of 0.069Gy/h, Cs-131 has a higher dose rate of 0.342 Gy/h. In
essence, this means that after the implant with Cs-131, 90% the dose is absorbed by 33 days,
in contrast with 32% of the dose absorption that occurs with I-125. This short t 1/2 life of
9.69 days (compared with 59.4 days for I-125) ensures shorter average life of the radioactive
seed, which not only ensures increased safety to the family and treating physicians but also
provides an early possibility of initiating adjuvant systemic therapy after only 1 month of
implantation. In this current series there was one patient who required re-operation for a
dural tear at 1.2 months post-implant. Due to the short t 1/2 of Cs-131 there was no risk of
exposure to the surgical team at that time point. The high mean energy of Cs-131 of 29 keV
allows fewer radioactive seeds to be implanted per given volume. Dosimetric studies
comparing various isotopes in prostate cancer have shown superiority of Cs-131 to I-125
and Palladium-103.60
Another reason for our success may be a higher rate of gross total resection of the tumors or
more careful, conformal placement of the seeds to prevent areas of inadequate dosing.
Clearly, careful attention to technical details will increase the success of any treatment.
Complicating the use of interstitial brachytherapy is the gradual shrinkage of the resection
cavity, which is a poorly understood process that progressively moves the seeds closer
together over time.3,13,26,60 However, cavity shrinkage would likely result in pockets of
higher dose delivery and higher rates of radiation necrosis, which we did not observe. We
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undertook several measures to decrease the degree of cavity shrinkage once the seeds were
placed. The seeds were not placed as individual seeds but were attached by strings with
tensile strength. These strings lined the cavity like barrel stave maintaining a certain amount
of outward pressure on the cavity to keep it from collapsing. Likewise, fibrin glue was
placed over the seeds not only to keep them from moving but to create additional outward
pressure on the cavity to prevent cavity shrinkage. Since the majority of the mass effect of
the tumor bulk was relieved after the initial surgery, indicated by the 69.6% shrinkage in
cavity volume prior to seed placement, the maintenance of a smaller residual volume during
the treatment period did not compromise the surgical goal of relieving mass effect.
Limitations
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In this analysis, we report results of the initial 24 patients. More substantial numbers of
patients from other institutions treated in such a manner will be required to make more
definitive conclusions. Likewise, randomized comparisons between brachytherapy and SRS
are indicated. The details of the kinetics and dynamics of the size and shape of the resection
cavity and its changes over time will be required for more precise treatment planning and
these studies are ongoing. Finally, formal objective measures of QoL and cognitive
processing as well as cost will help in comparing Cs-131 brachytherapy with other treatment
options.

Conclusions
This is the first prospective report of patients with newly diagnosed metastases treated with
maximally safe neurosurgical resection and intra-operative application of Cs-131. To date,
this method of brachytherapy, based on our institutional nomogram and surgical technique,
has rendered excellent local control, proved to be safe and efficacious. A multi-center trial
will soon be underway to evaluate this novel radioisotope as a promising treatment modality
in the treatment of patients with brain metastases requiring neurosurgical intervention.
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Abbreviations
WBRT

Whole brain radiotherapy

Cs-131

Cesium-131

SRS

stereotactic radiosurgery

FFP

freedom from progression

OS

overall survival

Qol

quality of life

I-125

Iodine-125
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HSRT

hypofractionated stereotactic radiotherapy
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Figure 1.
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Resection cavity throughout the implant procedure. A: Empty resection cavity B: Resection
Cavity lined like “barrel staves” or “parallel tracks” with Cs-131 seeds C: Cs-131 seeds
covered with Surgical (Ethicon) D: Cs-131 seeds covered with Tisseel (Baxter).
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Figure 2.

CT scan of Cs-131 brachytherapy seeds in the postoperative resection cavity. A: Axial plane
B: Sagittal plane. C: Coronal plane. D: 3-D Radiation cloud from the 80 Gy Isodose Line.
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Figure 3.

Overall Survival.
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Figure 4.

MRI series of local FFP. A: Pre-op B: Post-op C: 1 Month Post-op D: 2 Months Post-op E:
4 Months Post-op F: 6 Months Post-op G: 11 Months Post-op H: 13 Months Post-op.
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Figure 5.
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Regional Resection FFP.
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Figure 6.

MRI series of regional recurrence. A: Pre-op B: Post-op C: 1 Month Post-op D: 4 Months
Post-op E: 7 Months Post-op.
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Figure 7.

New Metastases FFP.
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